Besides, in a phase II study, 30 breast cancer patients undergoing radiotherapy following completion of their chemotherapy have been analyzed in order to investigate the curcumin potential versus placebo to reduce the DNA binding of NF-κB and the activation of its downstream target. The gene discussed is NFKB1; the disease is breast cancer.